Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

J Donald Easton; Renato D Lopes; M Cecilia Bahit; Daniel M Wojdyla; Christopher B Granger; Lars Wallentin; Marco Alings; Shinya Goto; Basil S Lewis; Mårten Rosenqvist; Michael Hanna; Puneet Mohan; John H Alexander; Hans-Christoph Diener; ARISTOTLE Committees and Investigators

doi:10.1016/S1474-4422(12)70092-3

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

J Donald Easton, Renato D Lopes, M Cecilia Bahit, Daniel M Wojdyla, Christopher B Granger, Lars Wallentin, Marco Alings, Shinya Goto, Basil S Lewis, Mårten Rosenqvist, Michael Hanna, Puneet Mohan, John H Alexander, Hans-Christoph Diener, ARISTOTLE Committees and Investigators

262 Citationer (Scopus)

Abstract

In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.

Originalsprog	Engelsk
Tidsskrift	Lancet Neurology Network
Vol/bind	11
Udgave nummer	6
Sider (fra-til)	503-11
Antal sider	9
ISSN	1470-8582
DOI	https://doi.org/10.1016/S1474-4422(12)70092-3
Status	Udgivet - jun. 2012

Adgang til dokumentet

10.1016/S1474-4422(12)70092-3

Citationsformater

Easton, J. D., Lopes, R. D., Bahit, M. C., Wojdyla, D. M., Granger, C. B., Wallentin, L., Alings, M., Goto, S., Lewis, B. S., Rosenqvist, M., Hanna, M., Mohan, P., Alexander, J. H., Diener, H.-C., & ARISTOTLE Committees and Investigators (2012). Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurology Network, 11(6), 503-11. https://doi.org/10.1016/S1474-4422(12)70092-3

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. / Easton, J Donald; Lopes, Renato D; Bahit, M Cecilia et al.
I: Lancet Neurology Network, Bind 11, Nr. 6, 06.2012, s. 503-11.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Easton, JD, Lopes, RD, Bahit, MC, Wojdyla, DM, Granger, CB, Wallentin, L, Alings, M, Goto, S, Lewis, BS, Rosenqvist, M, Hanna, M, Mohan, P, Alexander, JH, Diener, H-C & ARISTOTLE Committees and Investigators 2012, 'Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial', Lancet Neurology Network, bind 11, nr. 6, s. 503-11. https://doi.org/10.1016/S1474-4422(12)70092-3

@article{77a39e04ac684800b0f4aaaa81c28afb,

title = "Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial",

abstract = "In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.",

keywords = "Aged, Anticoagulants, Atrial Fibrillation, Double-Blind Method, Female, Humans, Intention to Treat Analysis, Ischemic Attack, Transient, Male, Proportional Hazards Models, Pyrazoles, Pyridones, Stroke, Treatment Outcome, Warfarin",

author = "Easton, {J Donald} and Lopes, {Renato D} and Bahit, {M Cecilia} and Wojdyla, {Daniel M} and Granger, {Christopher B} and Lars Wallentin and Marco Alings and Shinya Goto and Lewis, {Basil S} and M{\aa}rten Rosenqvist and Michael Hanna and Puneet Mohan and Alexander, {John H} and Hans-Christoph Diener and {ARISTOTLE Committees and Investigators} and Torp-Pedersen, {Christian Tobias}",

year = "2012",

month = jun,

doi = "10.1016/S1474-4422(12)70092-3",

language = "English",

volume = "11",

pages = "503--11",

journal = "Lancet Neurology Network",

issn = "1470-8582",

publisher = "TheLancet Publishing Group",

number = "6",

}

TY - JOUR

T1 - Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack

T2 - a subgroup analysis of the ARISTOTLE trial

AU - Easton, J Donald

AU - Lopes, Renato D

AU - Bahit, M Cecilia

AU - Wojdyla, Daniel M

AU - Granger, Christopher B

AU - Wallentin, Lars

AU - Alings, Marco

AU - Goto, Shinya

AU - Lewis, Basil S

AU - Rosenqvist, Mårten

AU - Hanna, Michael

AU - Mohan, Puneet

AU - Alexander, John H

AU - Diener, Hans-Christoph

AU - ARISTOTLE Committees and Investigators

AU - Torp-Pedersen, Christian Tobias

PY - 2012/6

Y1 - 2012/6

N2 - In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.

AB - In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA.

KW - Aged

KW - Anticoagulants

KW - Atrial Fibrillation

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Intention to Treat Analysis

KW - Ischemic Attack, Transient

KW - Male

KW - Proportional Hazards Models

KW - Pyrazoles

KW - Pyridones

KW - Stroke

KW - Treatment Outcome

KW - Warfarin

U2 - 10.1016/S1474-4422(12)70092-3

DO - 10.1016/S1474-4422(12)70092-3

M3 - Journal article

C2 - 22572202

SN - 1470-8582

VL - 11

SP - 503

EP - 511

JO - Lancet Neurology Network

JF - Lancet Neurology Network

IS - 6

ER -

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater